1750 - Testing of tumour tissue to detect IDH1 mutations in patients with cholangiocarcinoma to determine eligibility for ivosidenib on the Pharmacutical Benefits Scheme

Page last updated: 03 October 2023

Application Detail

Description of Medical Service

Testing of tumour tissue by a pathologist, for patients with locally advanced or metastatic Cholangiocarcinoma, to detect IDH1 mutations. Confirmation of the disease will be required to determine eligibility for treatment with TibsovoŽ (ivosidenib), which is seeking PBS listing through a codependent submission.

Description of Medical Condition

Cholangiocarcinoma is a type of cancer that encompasses all tumours originating from the epithelium of the bile duct. Bile ducts are a group of thin tubes that carry bile (a digestive fluid) from the liver and gallbladder into the intestines.

Reason for Application

New MBS item

Medical Service Type

Investigative technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Summary and PICO Set

Application Summary (PDF 401 KB)
Application Summary (Word 27 KB)

PICO Set (PDF 834 KB)
PICO Set (Word 300 KB)

Consultation Survey

Consultation Survey (PDF 654 KB)
Consultation Survey (Word 27 KB)

PASC Consultation
Consultation closed

MSAC Consultation
MSAC consultation TBA – please subscribe to the MSAC Email Bulletin to be notified when consultation opens for this application

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

PICO Confirmation (Word 728 KB)
PICO Confirmation (PDF 973 KB)

Assessment Report


Public Summary Document


Meetings for this Application


10-11 August 2023